Study Completed

Contraception

Bayer Identifier:

15002

ClinicalTrials.gov Identifier:

Not Available

EudraCT Number:

2009-017699-26

EU CT Number:

Not Available

Bioavailibility/Bioequivalence of Yaz/Nardis (Russia)

Trial purpose

Please see attached Study Results Summary below

Key Participants Requirements

Sex

N/A

Age

55 - 75 Years

Trial summary

Enrollment Goal

Trial Dates

March 2010 - May 2010

Phase

Phase 1

Could I Receive a placebo

N/A

Products

EE/DRSP (Yasmin Product Family)

Accepts Healthy Volunteer

N/A

Where to participate

Status	Institution	Location
Completed	SocraTec R&D Clinical Ward	Erfurt, 99084, Germany

Trial design

Characterization of relative bioavailability and assessment of bioequivalence of Nardis (Test) in comparison to Yaz (Reference) both containing 3 mg drospirenone and 0.02 mg ethinylestradiol in a single dose, two way crossover, open, randomized study under fasting conditions in postmenopausal women

Trial Type

Interventional

Intervention Type

N/A

Trial Purpose

N/A

Allocation

N/A

Blinding

N/A

Assignment

N/A

Trial Arms

N/A

Additional Information

Click here and search for drug information provided by the FDA.Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.